Article
Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention
Registro en:
LOCKWOOD, Diana N. J. et al. Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention. PLOS Neglected Tropical Diseases, [San Francisco], v. 12, n. 6, p. 1-4, jun. 2018.
1935-2727
10.1371/journal.pntd.0006403
Autor
Lockwood, Diana N.
Krishnamurthy, Padebettu
Kumar, Bhushan
Penna, Gerson Oliveira
Resumen
Gerson Oliveira Penna - Fundação Oswaldo Cruz. Fiocruz Brasília. Brasília, DF, Brasil. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento. Single-dose rifampicin (SDR) treatment being offered to household contacts of new leprosy patients is being practiced by the Indian National Leprosy Programme since November 2017. We are concerned, because this is not an effective method for preventing multibacillary (MB) leprosy. It does not protect against the development of MB leprosy and does not protect immediate household contacts for a reasonable period of time. There are serious ethical problems related to identifying the contacts of patients with leprosy, it is not cost effective for household contacts, and there is a possibility of the widespread use of SDR promoting the development of rifampicin resistance genes in Mycobacterium leprae.